No Data
No Data
No Data
No Data
No Data
Optimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy Data
TipRanks18:26
Dyne Therapeutics (DYN.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.81 dollars, previous value of -0.78 dollars, expected value of -0.80 dollars.
Dyne Therapeutics (DYN.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.81 dollars, previous value of -0.78 dollars, expected value of -0.80 dollars.
Zhitong Finance07:00
Dyne Therapeutics 1Q Loss/Shr 81c >DYN
Dyne Therapeutics 1Q Loss/Shr 81c >DYN
Dow Jones04:10
Dyne Therapeutics 1Q Loss $65.6M >DYN
Dyne Therapeutics 1Q Loss $65.6M >DYN
Dow Jones04:10
Press Release: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Ant
Dow Jones04:10
Dyne Therapeutics Price Target Announced at $40.00/Share by Morgan Stanley
Dyne Therapeutics Price Target Announced at $40.00/Share by Morgan Stanley
Dow JonesApr 30 17:27
No Data
No Data